Pattern of Admitted Cases in Respiratory Intensive Care Unit at Assiut University Hospitals

September 27, 2017 updated by: Mahmoud Badwy, Assiut University

Human health comprises many different states, ranging from perfect health to critical illness, so medical facilities should be able to provide medical assistance tailored to the patient's degree of disease.

The Intensive Care Unit (ICU) serves as a place for monitoring and care of patients with potentially severe physiologic instability requiring technical and/or artificial life support. The level of care in an ICU is greater than that available on the floor or Intermediate Care Unit.

Because of the utilization of expensive resources, ICUs should, in general, be reserved for those patients with reversible medical conditions who have a "reasonable prospect of substantial recovery".

About one third of hospital mortality occurs in critically ill patients in the intensive care unit. On the other hand, critically ill patients are responsible for 10 - 20 % of global hospital costs.

It is well accepted that early appropriate referral of patients to an ICU can significantly reduce early and possibly late mortality in the critically ill.At the same time improper selection of patients for ICU who block ICU beds often limits bed availability in ICUs. This in turn adversely affects the dynamics the whole hospital.

The Respiratory Intensive Care Unit (RICU) is an area that provides closed monitoring and intensive treatment for patients with acute or exacerbated respiratory failure caused by a disease that is primarily respiratory.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 86 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Only patients admitted to repiratory ICU

Description

Inclusion Criteria:

Patients with the following conditions are candidates for admission to the respiratory Intensive Care Unit. The following conditions include, but are not limited to:

  1. Acute respiratory failure requiring ventilatory support
  2. Acute pulmonary embolism with haemodynamic instability
  3. Massive haemoptysis
  4. Upper airway obstruction

Exclusion Criteria:

Patients who are generally not appropriate for respiratory ICU admission:

  1. Irreversible brain damage
  2. End stage cardiac, respiratory and liver disease with no options for transplant
  3. Metastatic cancer unresponsive to chemotherapy and/or radiotherapy
  4. Patients with non-traumatic coma leading to a persistent vegetative state (7,8,9,10)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Observational
Patterno of admitted cases in Respiratory Intensive Care Unit at Assiut University Hospitals and Outcome
To determine different patterns of admission and their Outcome

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The purpose of study is determine prognosis of patients admitted in Respiratory Intensive Care Unit at Assiut University Hospitals.
Time Frame: First 24hours of admission.
Assessment of Acute Physiology and Health Evaluation II (APHCHE II) score of each admitted case.
First 24hours of admission.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mahmoud Badwy, Resident, Assiut University
  • Study Director: Yousef Ahmad, Prof, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

September 1, 2018

Primary Completion (Anticipated)

September 1, 2019

Study Completion (Anticipated)

March 1, 2020

Study Registration Dates

First Submitted

September 9, 2017

First Submitted That Met QC Criteria

September 27, 2017

First Posted (Actual)

September 28, 2017

Study Record Updates

Last Update Posted (Actual)

September 28, 2017

Last Update Submitted That Met QC Criteria

September 27, 2017

Last Verified

September 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • Mahmoud Badwy2017

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data will be available for primary Outcome

IPD Sharing Time Frame

Data will be available within 6 months from study completion

IPD Sharing Access Criteria

Data access will be reviewed by internal independent review panel

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD Exacerbation

Clinical Trials on Observational

3
Subscribe